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Headache Questionnaire, and some additional items to
document medication and satisfaction with general ther-
apy. General information about management and preven-
tion of headache was offered to the 341 respondents suf-
fering from headache, as well as to physicians and
pharmacists. In a second survey, questionnaires were filled
out by the participants to record the impact of the pro-
gram.
RESULTS: Results from the first survey were reported by
Göbel et al. (Cephalalgia 17[1997]325). Of the 183 trace-
able initial respondents, 68.9% took part in the final sur-
vey: 29.1% of the participants reported an improvement
in health status; 43.1% stated fewer headaches; 38.9%
reported shorter headache attacks; 22.6% had better
knowledge to identify trigger factors; 21.0% reduced
their consumption of medication; and 41.9% learned an
active relaxation technique. Together with other exten-
sive healthcare measures initiated through the company,
there was a reduction of lost labor time due to illness.
CONCLUSION: It is possible to create a network between
employees, physicians, pharmacists, the sick fund, and the
pharmaceutical industry to successfully address the ques-
tion of headache management within a work-site environ-
ment. Unmet medical needs can be identified, and aware-
ness for intervention programs can be raised through
studies using general headache questionnaires. The infor-
mation of patients as well as physicians and pharmacists
reduced the burden of headache and improved the out-
comes of headache treatment. More collaborative efforts
to improve the unsatisfactory situation of headache pa-
tients and migraine patients are needed.
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The identification of cost components deriving from di-
rect and indirect consequences of disease is a fundamen-
tal step in conducting cost-effectiveness (CE) analysis. In
time-constrained efforts to collect CE data for inclusion
in a product’s commercial development dossier, little at-
tention is likely to be paid to fundamental research. Cou-
pled with other early research components, such as ex-
pert and/or patient interviews, a prior comprehensive
review of the literature can ensure a strong foundation on
which robust economic arguments could subsequently be
formulated.
OBJECTIVE: The objective of this research was to ex-
plore and define 1) cost drivers and 2) clinical endpoints
representing global treatment effectiveness in Parkinson’s
disease (PD).
METHODS: A review of the published literature in PD
was conducted, surveying elements including:
• Contemporary treatment options and costs;
• Clinical markers measuring progression;
• Indirect morbidity and related costs.
The geographic foci of the research were Germany and
the UK.
RESULTS: A global indicator of symptoms and compli-
cations of PD treatment is the Unified Parkinson’s Dis-
ease Rating Scale (UPDRS); significant events represent-
ing complications and co-morbidity include prevalence
and severity of motor complications—dyskinesias, de-
pression, dementia, and postural imbalance—leading to
falls and other accidents. Hospitalization accounts for
50% to 90% of costs of PD care in Germany and the UK,
followed by medication costs. The main determinants of
hospitalization rates are disease stage, akinetic type of dis-
ease and presence of motor fluctuations in spite of, as well
as in relation to, therapy. 
CONCLUSIONS: In collecting economic data for PD
treatment, the definitive demonstration of CE must in-
clude improved long-term efficacy, safety, and reduced
rates of direct and indirect resource utilization—in partic-
ular, hospitalization.
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OBJECTIVE: Patient outcome measures of health utility
and functional status were used to assess sensitivity to
drug treatment and its relationship to PD severity.
BACKGROUND: A multicenter trial in seven countries
compared the safety, tolerance, and efficacy of pramipex-
ole (to 4.5 mg) and bromocriptine (to 30 mg) in advanced
PD. Patients (N  247, 80 pramipexole, 84 bromocrip-
tine, 83 placebo) were male and female, in- and out-
patients, 30 years and older, with advanced idiopathic
PD (stages II-IV Hoehn and Yahr [H&Y]), with motor
fluctuations characterized as end-of-dose phenomena.
Each received individually optimized dosages of levo-
dopa. (Guttman et al., “Double-blind comparison of pra-
mipexole and bromocriptine treatment with placebo in
advanced Parkinson’s disease,” [Neurology 49:Oct 1997,
1060–1065]).
METHODS: Patients were treated for up to 9 months, 11
days: 1) ascending dose up to 3 months, 2) maintenance
dose for approximately 6 months, and 3) decreasing dose
up to 11 days. Primary efficacy endpoints were: UPDRS
II—Activities of Daily Living (ADLs), averaged over “on”
and “off” periods, and UPDRS III—Motor Examination
during “on” periods. Secondary endpoints included the
EuroQoL visual analog scale (VAS) and Functional Status
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Questionnaire (FSQ). Analyses were based on differences
between baseline and final measures.
RESULTS: Significant differences (p  0.05) in FSQ sub-
scores were found in Basic ADLs, Intermediate ADLs,
and Mental Health, for both pramipexole and bro-
mocriptine compared with placebo. Pramipexole patients
scored significantly higher than placebo patients, while
bromocriptine patients did not, on FSQ Intermediate
ADLs, Usual Activity Days Reduced, and EuroQol VAS.
FSQ and EuroQoL scores declined with increasing PD se-
verity, as assessed by H&Y on FSQ domains—Basic
ADLs, Intermediate ADLs, Social Activities, Quality of
Interaction—and on FSQ single items—Days Cut Down
on Usual Activities Due to Illness/Injury and Satisfaction
with Sexual Relationship, as well as the EuroQoL VAS. 
CONCLUSIONS: The EuroQoL VAS and some do-
mains/items of the FSQ were sensitive to drug treatment.
An inverse relationship was revealed between EuroQol
VAS scores and some FSQ scores and PD severity.
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OBJECTIVE: With the increase of QoL assessment in
clinical trials, it is necessary to have cross-culturally valid
instruments to pool data across countries. The FAMS, a
59-item instrument designed in US English, assesses six
domains of multiple sclerosis.
METHODS: Prior to use in an international trial, the
FAMS needed to undergo cross-cultural adaptation in
nine languages. This involved the recruitment of a QoL
specialist in each target country. Two independent for-
ward translations were produced by native speakers, rec-
onciled and then back-translated into English. The trans-
lations were tested for comprehension in a sample target
population, compared and internationally harmonized.
The developer clarified concepts underlying each item.
Translation problems involved finding conceptual equiv-
alents of typical US expressions and the response catego-
ries. For example, a literal translation of the term “so-
cial activity,” referring to humanitarian work in certain
languages, required a descriptive equivalent. Translating
“getting around in public places” necessitated lengthy de-
scriptions in certain languages to retain the original con-
cept. The neutral term “condition” could not be retained
in certain translations, where a reference to “health
state” or even “illness” was the best compromise. Patient
testing showed that a response option “not applicable”
was lacking and that answers should refer more clearly to
the introductory sentence. To harmonize with the vali-
dated original, however, no changes were made in the re-
sponse categories. 
CONCLUSIONS: Before use in an international trial, rig-
orous cultural adaptation was essential in producing cross-
culturally valid language versions. The integration of
changes to the responses in an updated form of the instru-
ment might require further validation. Further responsive-
ness data will be generated by the clinical trial. Ideally, ini-
tial instrument design should include international input.
PN6
IMPACT OF A COST-SHARING DRUG 
INSURANCE PLAN ON DRUG UTILIZATION 
AMONG INDIVIDUALS RECEIVING
SOCIAL ASSISTANCE
LeLorier J, Blais L, Couture J, Rahme E
Centre de recherche, Centre hospitalier de l’Université de 
Montréal, Campus Hôtel-Dieu, Québec, Canada
OBJECTIVE: In August 1996, the Régie de l’assurance-
maladie du Québec (RAMQ) introduced a new drug in-
surance plan for all residents of the Canadian province of
Québec. Before this insurance plan, individuals receiving
social assistance had all their medications paid for by the
RAMQ. Now, they have to pay up to $50 per quarter for
their medications in terms of deductible and co-insur-
ance. Concerned that this financial constraint could have
an impact on the use of medications, we investigated
whether the consumption of three classes of medications
(neuroleptics, anticonvulsants, and inhaled corticoster-
oids) had been modified after the new drug plan was in-
troduced.
METHODS: Using time series analysis and the computer-
ized databases of the RAMQ, we analyzed the variation
in the number of prescriptions dispensed per month for
each drug class from August 1992 to July 1997.
RESULTS: Users of inhaled corticosteroids were the most
affected, with a statistically significant decrease of 28%
in the number of dispensed prescriptions for the 11
months following the inception of the drug plan (August
1996 to June 1997) as compared with the same period 1
year before. For the same period, we expected an increase
of 9% according to the trend seen from August 1992 to
July 1996. For users of neuroleptics and anti-convulsants
we found a 1% decrease for each, expecting increases of
7% and 8%, respectively. 
CONCLUSIONS: Following the introduction of the
Québec drug plan, individuals receiving social assistance
significantly decreased their consumption of inhaled cor-
ticosteroids, medications that are considered to be effec-
tive and essential.
